Mutations in phosphatase and tensin homologue (PTEN) or genomic alterations in the phosphatidylinositol-3-OH kinase-signalling pathway are the most common genetic alterations reported in human prostate cancer [1] [2] [3] [4] . However, the precise mechanism underlying how indolent tumours with PTEN alterations acquire metastatic potential remains poorly understood. Recent studies suggest that upregulation of transforming growth factor (TGF)-b signalling triggered by PTEN loss will form a growth barrier as a defence mechanism to constrain prostate cancer progression 5 , underscoring that TGF-b signalling might represent a pre-invasive checkpoint to prevent PTEN-mediated prostate tumorigenesis. Here we show that COUP transcription factor II (COUP-TFII, also known as NR2F2) [6] [7] [8] [9] , a member of the nuclear receptor superfamily, serves as a key regulator to inhibit SMAD4-dependent transcription, and consequently overrides the TGF-b-dependent checkpoint for PTEN-null indolent tumours. Overexpression of COUP-TFII in the mouse prostate epithelium cooperates with PTEN deletion to augment malignant progression and produce an aggressive metastasisprone tumour. The functional counteraction between COUP-TFII and SMAD4 is reinforced by genetically engineered mouse models in which conditional loss of SMAD4 diminishes the inhibitory effects elicited by COUP-TFII ablation. The biological significance of COUP-TFII in prostate carcinogenesis is substantiated by patient sample analysis, in which COUP-TFII expression or activity is tightly correlated with tumour recurrence and disease progression, whereas it is inversely associated with TGF-b signalling. These findings reveal that the destruction of the TGF-b-dependent barrier by COUP-TFII is crucial for the progression of PTEN-mutant prostate cancer into a life-threatening disease, and supports COUP-TFII as a potential drug target for the intervention of metastatic human prostate cancer.
COUP-TFII is known to promote tumour angiogenesis through its function in the tumour microenvironment 10, 11 , but its role in tumour cells remains undefined. Consistent with aberrant expression of COUP-TFII reported in various tumours [12] [13] [14] [15] [16] [17] , Oncomine expression analysis revealed higher COUP-TFII expression in prostate tumour cells and in metastatic prostate cancer than in primary prostate cancer 12, 13 ( Supplementary Fig. 1a ). To assess the clinical relevance of COUP-TFII in human prostate cancer, we stained for COUP-TFII in a tumour tissue microarray (TMA) consisting of 407 patient specimens. Examination of clinical prostate specimens showed higher levels of COUP-TFII expression in prostate tumour cells in comparison to the adjacent normal prostate epithelium ( Supplementary Fig. 1b ). As summarized in Fig. 1a , approximately 60% of human prostate cancer specimens exhibited intermediate to intense nuclear COUP-TFII staining, whereas only 5% of normal prostate epithelial cells stained positive for COUP-TFII. Further correlation studies indicated that COUP-TFII expression in tumour cells significantly associated with pathological predictors of human prostate cancer aggressiveness (Supplementary Table 1 ). Most importantly, univariate analysis indicated that COUP-TFII expression levels in prostate tumour cells could serve as a predictor to stratify risk of recurrence in patients; patients bearing higher levels of COUP-TFII expression showed earlier recurrence after radical prostatectomy (Fig. 1b) . Cox proportional hazards regression analyses showed that tumour recurrence was sensitive to gradual increases of COUP-TFII expression levels, as reflected by the increasing hazard ratios, from 1.5 to 1.8 and 2.5.
These results prompted us to use genetically engineered mouse models to determine the causal role of COUP-TFII in prostate tumorigenesis. As such, we engineered mice containing PB-Cre (the Cre gene under control of the prostate-specific probasin promoter) 18 and conditional knockout alleles of Pten 3 and/or COUP-TFII (also known as Nr2f2) 7 , hereafter referred to as Pten PC2/2 and Pten PC2/2
; COUP-TFII PC2/2 mice, respectively ( Supplementary Fig. 2a, b) . PTEN-null mice lacking COUP-TFII exhibited a significant reduction in prostate weight ( Supplementary Fig. 2c ), suggesting a positive role for COUP-TFII in driving prostate tumorigenesis. Histopathological analysis of the entire animal cohort showed that loss of COUP-TFII compromised prostate tumour progression, as reflected by the arrest of tumours at the hyperplastic or low-grade prostatic intraepithelial neoplasia (PIN) stage at 5 months of age, whereas tumours from Pten PC2/2 mice already advanced to high-grade PIN or adenocarcinoma (Fig. 1c, d and Supplementary Fig. 2d ). The normal prostatic histology in COUP-TFII PC2/2 mice ( Supplementary Fig. 2e ) argued against a possibility that it was due to a developmental defect. Moreover, loss of COUP-TFII attenuated the proliferation advantage elicited by PTEN loss, whereas the levels of angiogenesis remained similar and thus is unlikely to have contributed to the restriction of prostate tumorigenesis ( Supplementary Fig. 2f, g ).
Given that COUP-TFII was further upregulated in metastatic prostate cancer, and its higher expression correlated with a worse clinical outcome, we sought to determine whether overexpression of COUP-TFII in PTEN-null tumours would exacerbate prostate tumorigenesis. As such, we generated an inducible COUP-TFII overexpression mouse, COUP-TFII OE/1 (Fig. 2a) , that allows constitutive COUP-TFII expression in the prostate epithelium. During 12 months of follow-up, COUP-TFII OE/1 mice exhibited normal prostatic histology (Supplementary Fig. 3a) , indicating that COUP-TFII by itself is not sufficient to initiate prostate neoplasia, and that cooperating oncogenic lesions are required. Indeed, overexpression of COUP-TFII in a PTEN-heterozygous background resulted in a rapid acceleration of tumour progression, with overt and high penetrance PIN starting at 4 months of age and progressing to high-grade PIN or adenocarcinoma by 12 months (Fig. 2b ). These data demonstrate that COUP-TFII enables rapid disease progression from preneoplastic prostatic epithelium.
Next, we determined whether prostate-specific overexpression of COUP-TFII in a PTEN-null background would produce a metastasis-prone cancer. By 24 weeks of age, Pten PC2/2 ; COUP-TFII OE/1 mice developed highly aggressive carcinoma with an altered stroma, as evidenced by the attenuation or loss of the periglandular smooth muscle layer and androgen receptor (AR)-positive tumour cells invading into the stroma (Fig. 2c) , in which subsets of invasive tumour cells exhibited epithelial-mesenchymal transition ( Supplementary Fig. 3c ). Molecular pathological analysis of prostate-cancer-bearing Pten PC2/2 ; COUP-TFII OE/1 mice also showed a metastatic spread of AR-positive tumour nodules to lumbar lymph nodes in 13 out of 16 cases, and lung metastasis in 4 out of 16 cases (Fig. 2d) . By contrast, Pten PC2/2 mice only showed a modest metastatic phenotype [2] [3] [4] . Even with more aggressive tumour phenotypes, angiogenesis was not altered whereas proliferation was enhanced after COUP-TFII overexpression ( Fig. 2e and Supplementary Figs 3d, e and 4). Collectively, COUP-TFII overexpression enhances the full spectrum of prostate cancer development, leading to aggressive metastasis in PTEN-null tumours.
To determine how COUP-TFII affects tumorigenesis, we conducted a transcriptome comparison using COUP-TFII-depleted PC3 cells. Unbiased ingenuity pathway analysis indicated that COUP-TFII was crucial for the growth of human prostate cancer cells, an observation reinforced by anchorage-independent growth assays and cell proliferation/viability tests (MTT assay) ( Supplementary Fig. 5 ). Further gene-set enrichment analysis and comparison with our gene expression profile to a defined TGF-b response signature 19 indicated a global enrichment of TGF-b-induced genes in the absence of COUP-TFII ( Fig. 3a and Supplementary Fig. 6a ). Given that TGF-b signalling is crucial for prostate cancer progression 5, 20 , we examined whether COUP-TFII potentiated prostate tumorigenesis through TGF-b signalling. In human prostate cancer cells, COUP-TFII served as a transcriptional inhibitor of TGF-b signalling (Supplementary Fig. 6b-d) . Knockdown of COUP-TFII in PC3 cells substantially altered p21, p15 and cyclin D1 expression in response to TGF-b stimulation ( Supplementary Fig. 6e ). Protein levels of p21 were also increased without TGF-b stimulation, presumably owing to autocrine TGF-b signalling in PC3 cells ( Supplementary Fig. 6f ).
We postulated that overexpression of COUP-TFII enabled the indolent PTEN-null tumours to acquire metastatic potential through the destruction of a TGF-b-induced growth barrier. Indeed, in ; COUP-TFII OE/1 mice, the TGF-b-induced growth barrier was significantly attenuated after increased COUP-TFII expression (Fig. 3b) . Overexpression of COUP-TFII profoundly neutralized oncogene-induced senescence, as judged by the reduction of senescenceassociated b-galactosidase staining ( Supplementary Fig. 6g ), whereas ablation of COUP-TFII in PTEN-null mice enhanced the acquisition of hyperactivity of TGF-b signalling and a marked induction in cellular senescence. Furthermore, the clinical relevance between COUP-TFII levels and TGF-b signalling activities was established by a significant correlation between COUP-TFII and p21/cyclin D1 expression in prostate tumours, but not in normal prostate epithelium counterparts, in a cohort of 36 patients with highly aggressive prostate cancer (Fig. 3c) .
Next, we extended our findings by querying the gene expression profiling data set GSE10645 (ref. 21 ) that contains 596 primary human tumours with prostate cancer-specific death information, to complement our TMA results. Using gene expression profiles obtained in PC3 cells, we found a total of 80 COUP-TFII-regulated genes represented in GSE10645 (Methods, Supplementary Fig. 7 and Supplementary Table 2); the genes were used to score each of the human tumours for COUP-TFII activity. We observed distinct differences in the time to prostate-cancer-specific death, although no differences in the time to prostate-specific antigen (PSA) recurrence, among the patients with higher versus lower COUP-TFII activity ( Fig. 3d and Supplementary Table 3-5). Multivariate Cox model analysis indicated that the PTEN, SMAD4, p21, cyclin D1 and COUP-TFII signature (Methods) all independently provided predictive power to stratify patients into highand low-risk groups (Fig. 3e) . Plotting the combined transcript levels of PTEN, SMAD4, p21 and cyclin D1 together with the higher COUP-TFII signature in prostatectomies increased the predictive power from that of either gene set alone (Fig. 3f) , illustrating a significant genetic cooperation between COUP-TFII and TGF-b signalling in PTEN-null human prostate cancer tumours.
Because depletion of COUP-TFII failed to affect the levels of SMAD2/3/4, the receptors or the activated form of phosphorylated-SMAD2/3 ( Supplementary Fig. 8 ), we investigated whether COUP-TFII could interact directly with any of these SMAD proteins. Indeed, COUP-TFII strongly associated with SMAD4 in cells ( Supplementary  Fig. 9a-c) and in patient tumour specimens (Fig. 4a) . Overexpression of mutant COUP-TFII-M2, which was unable to associate with SMAD4, failed to inhibit TGF-b signalling, indicating that the COUP-TFII-SMAD4 interaction was essential for the COUP-TFII effects on TGF-b signalling ( Supplementary Fig. 9d-f) . Mechanistically, our data indicated that COUP-TFII sequestered SMAD4 from binding to TGF-b-target gene promoters in cells (Supplementary Fig. 10 ) and in tumours containing higher levels of COUP-TFII (Fig. 4b) .
As supporting evidence for the counteraction between COUP-TFII and SMAD4, knockdown of SMAD4 in PC3 cells alleviated the proliferative defects exerted by COUP-TFII depletion ( Supplementary Fig. 11 ). Furthermore, we used a SMAD4 conditional knockout mouse 22 to examine the tumour spectrum in Pten ; Smad4 PC2/2 mice (Fig. 4c, d and Supplementary Figs 12-14 ; Smad4 PC2/2 mice (Fig. 4c, d and Supplementary Figs 12-14) . 
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In summary, our findings highlight a crucial role for COUP-TFII in driving full malignant progression of PTEN-null prostate tumorigenesis by counteracting TGF-b negative feedback signalling (Fig. 4e) . As COUP-TFII is a member of the nuclear receptor family, the activity of which can be regulated by small molecules 23 , our studies provide a potential new drug target for the intervention of metastatic human prostate cancer.
METHODS SUMMARY
Tissue microarrays used in this study were described previously 24, 25 . All animal experiments were approved by the Animal Center for Comparative Medicine at Baylor College of Medicine. Detailed materials, methods and statistical analysis are provided in the Methods. 
LETTER RESEARCH

METHODS
Immunohistochemistry and quantitative reverse transcriptase PCR analysis. Tissue microarrays used in this study were described previously 24, 25 . Samples were procured from radical prostatectomies of 416 patients, who received no adjuvant therapy such as radiation or hormonal therapy. Other patient characteristics were as described previously [24] [25] [26] . Immunohistochemical analyses were done as described [24] [25] [26] using a specific anti-COUP-TFII antibody (Perseus Proteomics). Samples were scanned using a Bliss automated slide scanner to generate highresolution digital images. The expression of COUP-TFII protein was scored and quantified as described previously 24, 25 . In brief, the slides were digitized and nuclear COUP-TFII protein expression was scored and quantified based on a multiplicative index of the average staining intensity (0-3) and extent of staining (0-3) in the cores, yielding a 10-point staining index that ranged from 0 (no staining) to 9 (extensive, strong staining). Quantitative PCR (qPCR) was performed on RNAs isolated from patients with prostate cancer (n 5 36) undergoing a radical prostatectomy for clinically localized prostate cancer with clinical characteristics as previously described 25 . The tissues were .70% cancerous based on histopathological analysis. were previously generated by our laboratory, and COUP-TFII OE/1 mice were generated by our group using an approach as previously described 27 . Pten , COUP-TFII OE/1 and Pten flox/flox mice were backcrossed with C57BL/6 mice for at least five generations, and maintained according to the National Institutes of Health Guide for the Care and Use of Laboratory. COUP-TFII-floxed or COUP-TFII OE/1 mice were first crossed with Pten-floxed or Smad4-floxed mice. The resulting compound mice were then crossed with PBCre mice for conditional knockout or overexpression of COUP-TFII in the prostate epithelium. Expression plasmids and siRNA. The full-length human COUP-TFII cDNA was cloned into pMSCV-puro/neo (Clontech), pcDNA5 (Flag tag) (Invitrogen) and pcDNA3.1 (Myc tag) (Invitrogen) to generate COUP-TFII expression plasmids. Overlapping PCR with primers was used to generate Flag-COUP-TFII-M1 and M2 constructs, which are inserted in the KPNI/NheI sites of pcDNA5. Expression plasmids for epitope-tagged SMAD2/3/4, glutathione S-transferase (GST)-SMAD4 and the SMAD-binding element (SBE)-Luc reporter were described previously 29 . COUP-TFII-specific short hairpin RNA (shRNA) constructs were generated previously 30 . In brief, the shRNA for COUP-TFII (59-AGGTAACGTGA TTGATTCAGTATCTTA-39 and 59-AGCTCTTGCTTCGTCTCCC-39) was cloned into pSUPER.retro (OligoEngine). SMART pool or single siRNA duplexes targeting COUP-TFII, Smad4 and control non-target siRNA were purchased from Dharmacon. Cell culture and reagents. PC3, VCaP, LNCaP and DU145 cells were obtained from the ATCC and cultured in DMEM or RPMI supplemented with 10% fetal bovine serum. RWPE-1 cells (ATCC) were cultured with keratinocyte serumfree medium (K-SFM; Invitrogen) with bovine pituitary extract and human recombinant EGF. Cells were transfected with siRNA duplexes (40-80 nM) using lipofectamine (Invitrogen) or Dharmacon transfection (Dharmacon) reagents according to the manufacturer's instructions. COUP-TFII retrovirus was generated and transfected as previously described 1 . In brief, cells were transduced with retrovirus and cultured with 2 mg ml 21 puromycin or 400 mg ml 21 neomycin and the selection was stopped as soon as the non-infected control cells died off. Cell proliferation assay was performed using CellTiter 96 non-radioactive cell proliferation assay (MTT) kit (Promega) assay according to the manufacturer's instructions. Results were calculated based on three independent experiments and statistical significance was determined by two sided Student's t-test. Luciferase reporter assay. Reporter assays were carried out as described 11 . In brief, 20-24 h after transfection, cells were treated with TGF-b (10 ng ml
21
) or SB431542 compound (20 nM) for 24 h. Cells were then collected for measurement of luciferase and b-galactosidase activities. All assays were done in duplicate and all values were normalized for transfection efficiency against b-galactosidase activities. Luciferase activity was determined with the Promega luciferase assay kit. Results were quantified based on three independent experiments and statistical significance was determined by two sided Student's t-test. P values less than 0.05 were considered significant. RNA isolation and qPCR. Total RNA was extracted using TRIzol followed by the RNeasy mini kit (Qiagen) cleanup and RQ1 RNase-free DNase set treatment (Promega) according to the manufacturer's instructions. First-strand cDNA was synthesized using 2 mg of total RNA and Superscript II (Invitrogen). TaqMan universal master mix reagents and inventoried primer/probe mixtures (Applied Biosytems) were used for the reaction. Standard curves were generated by serial dilution of a preparation of total RNA, and all messenger RNA quantities were normalized against 18S RNA using ABI ribosomal RNA control reagents. The primers/probes used in this study are as follows: COUP-TFII (Mm00772789_m1), AR (Hs00171172_m1), probasin (Mm00444381_m1), NKX3.1 (Mm00440479_m1) and p21 (Hs00355782_m1). A Student's t-test was used for statistical analysis of qPCR results, and P values less than 0.05 were considered significant. Histology and immunohistochemistry. The ventral, dorsolateral and anterior prostate lobes were dissected, fixed in 4% formaldehyde in PBS for 24 h, processed and embedded in paraffin. Sections (7 mm) were processed for H&E staining. Prostate hyperplasia is characterized by the proliferation of luminal cells with no cytological atypia, but contain small foci with two or three layers of cells. The PIN lesions were graded using the nomenclature and criteria developed previously 31 . In brief, high-grade PIN is characterized by an intraglandular proliferation of crowding cells with atypia, and cribriform formation or the development of multilayered solid glandular structures. Invasive adenocarcinoma is characterized by the proliferation of atypical cells that break the basal membrane and invade through the prostatic stroma. The quantitative results of tumour progression are from two random slides of each mouse in a total 10 pairs of the entire animal cohort. For immunohistochemistry, the slides were processed using a citratebuffer-based antigen retrieval and the avidin-biotin peroxidase immunohistochemistry method. Sections were counterstained with 49,6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich). Quantification of tumour malignancy was done as follows: for Ki67 staining, positive cells were counted after imaging with a Zeiss Axioplan microscope. Three random slides for each animal were counted. The proliferative rate was determined by counting the proliferating cells (Ki67-positive) in a total of 100 cells, and the statistical significance was determined with a two-tailed Student's t-test. For lymph node metastasis, we performed CK8 or AR immunostaining in lymph nodes and recorded the percentage of mice that were positive for CK8 or AR, which we considered as lymph node metastasis. For invasive adenocarcinoma identification, we performed SMAa immunostaining. If the gland or acini displayed a loss or breakdown of the continuous layer of basal membrane (SMAa-positive) and the appearance of AR-or CK8-positive epithelial cells invading into the stromal compartment, we consider it as microinvasive cancer. The statistical significance between groups was determined with a two-tailed Fisher extract test. Western blot and chromatin immunoprecipitation assay. Total proteins were extracted from cells following standard protocol 11 . Nuclear proteins were extracted using the NE-PER kit (Pierce). Protein concentration was measured using the BCA protein assay kit (Thermo Scientific). The primary antibodies used in this study were as follows: COUP-TFII (Perseus Proteomics), b-actin (Santa Cruz), phophorylated-H3 (Cell Signaling), PCNA (Santa Cruz), phospho-AKT403 (Cell Signaling), pan AKT (Cell Signaling), SMAD4 (Santa Cruz), p21 (BD), phospho-SMAD2 (Cell Signaling), SMAD2 (Zymed), SMAD3 (Zymed), cyclin D1 (Sigma), p15 (Santa Cruz) and p53 (Santa Cruz). Horseradish peroxidase (HRP)-conjugated secondary antibodies were purchased from DAKO. Signals were visualized with the Super Signal West Pico Chemiluminescent Substrate kit (Pierce). Chromatin immunoprecipitation assays were performed as described as previously 11 according to the protocol provided by Millipore. All the results are obtained from three independent samples and statistical significance was determined by a two-sided Student's t-test. Immunoprecipitation and western blot analysis. Immunoprecipitation was performed as described previously 3 . Endogenous or epitope-tagged proteins were immunoprecipitated from cell lysates by the appropriate antibody affinity gel as indicated in the text and figure legends. After extensive washes, immunoprecipitated proteins were eluted in SDS sample loading buffer (Bio-Rad), separated by SDS-PAGE, transferred to nitrocellulose (Pierce) and detected in western blots with appropriate primary antibodies coupled with HRP-conjugated secondary antibody by chemiluminescence (Pierce). GST fusion protein, in vitro protein binding and pull-down assays. GST fusion proteins were prepared using a commercial kit (Amersham Pharmacia Biotech). Target protein was pre-cleared with 5 mg of GST protein for 1 h and then incubated with 2 mg of various GST-fusion proteins for 2 h in the binding buffer (50 mM Tris-HCl, pH 7.5, 120 mM NaCl, 2 mM EDTA, 0.1% NP40). Proteins bound to GST-fusion proteins were retrieved on glutathione-sepharose beads, separated by SDS-PAGE and examined by western blot. Electrophoretic mobility shift assay. Nuclear proteins from PC3 cells treated with TGF-b for 1 h were extracted using NE-PER kit (Pierce). Complementary oligonucleotides corresponding to the p21 SBE and its mutants were annealed and end labelled with [c- 32 P]ATP. The binding reactions were performed and analysed on a 5% non-denaturing gel. For supershift studies, 1 mg of antibody against SMAD4 (Santa Cruz) was preincubated for 20 min on ice, and DNA-protein complexes were visualized by autoradiography. Microarray analysis. For microarray analysis, total RNA was isolated from control and COUP-TFII-knockdown PC3 cells. The Microarray Core at Baylor LETTER RESEARCH
